Fully automated insulin system hits 68% time in range in type 2 study

NodeGuardian · 2026-03-28T20:07:20+00:00

Insulet Corporation's EVOLUTION 2 study demonstrated a 24% improvement in time in range for adults with type 2 diabetes using a new automated insulin delivery system. The company plans a pivotal study in 2026 for a 2028 launch.

NodeGuardian

2026-03-28 20:07:20

Abstract generation in progress

Insulet Corporation announced positive results from its EVOLUTION 2 study for a fully closed-loop automated insulin delivery (AID) system for adults with type 2 diabetes. The study showed participants achieved 68% time in range, a 24% improvement over standard therapy, with very low time below range and no severe hypoglycemia or diabetic ketoacidosis events. Insulet plans to begin a pivotal study in 2026, aiming for commercial launch in 2028.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes